Chemoimmunotherapy With or Without Thoracic Radiotherapy for Elderly Patients in Advanced Non‐Small Cell Lung Cancer
International Journal of Cancer · 15.09.2026 · 159 (6) · 1385-1390
DOI: 10.1002/ijc.70551 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 12.05.2026. Verfasst von Zhiru Gao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Immunotherapy. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Technologies Research and Development Program, National Natural Science Foundation of China, Post-Marketing Clinical Research Special Project on Innovative Drugs.
Abstract (Originalsprache)
The optimal integration of thoracic radiotherapy (TRT) with first‐line chemoimmunotherapy for elderly patients with driver‐negative advanced non‐small cell lung cancer (NSCLC) remains undefined. We conducted a real‐world study to assess the efficacy and safety of this triple‐modality therapy specifically in patients aged ≥ 65 years. We designed a retrospective analysis of elderly patients with stage IV, mutation‐negative NSCLC who underwent first‐line platinum‐based chemotherapy combined with immunotherapy at our institution between November 2019 and September 2024. Overall survival (OS) and progression‐free survival (PFS) were estimated using the Kaplan–Meier method, and differences between groups were compared with the log‐rank test. After a median follow‐up of 22.34 months, the addition of TRT yielded numerically longer but statistically non‐significant median PFS (12.20 vs. 10.17 months; p = 0.24) and OS (29.67 vs. 18.65 months; p = 0.09). Subgroup analysis suggested a potential survival trend with triple therapy in patients aged 65–70 years, whereas no benefit was observed in those aged ≥ 70 years. Notably, treatment discontinuation due to adverse events was significantly more frequent in the Chemo+ICI+TRT group, with pneumonia being the predominant cause. For elderly patients with advanced NSCLC, particularly those aged ≥ 70 years, incorporating TRT into first‐line chemoimmunotherapy did not significantly improve survival but substantially increased toxicity, often leading to treatment interruption. A potential benefit observed in patients aged 65–70 years requires prospective validation. These results highlight the critical need for personalized treatment intensity in geriatric oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
ORCID-Profile: Linlin Wang
Förderung
- National Key Technologies Research and Development Program
- National Natural Science Foundation of China
- Post-Marketing Clinical Research Special Project on Innovative Drugs
- Natural Science Foundation of Shandong Province
- Collaborative Academic Innovation Project of Shandong Cancer Hospital
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
Zitieren
APA
Gao, Z., Yang, L., & Wang, L. (2026). Chemoimmunotherapy With or Without Thoracic Radiotherapy for Elderly Patients in Advanced Non‐Small Cell Lung Cancer. International Journal of Cancer, 159(6), 1385-1390. https://doi.org/10.1002/ijc.70551
Vancouver
Gao Z, Yang L, Wang L. Chemoimmunotherapy With or Without Thoracic Radiotherapy for Elderly Patients in Advanced Non‐Small Cell Lung Cancer. International Journal of Cancer. 2026;159(6):1385-1390. doi:10.1002/ijc.70551
BibTeX
@article{Gao2026,
author = {Gao, Zhiru and Yang, Linlin and Wang, Linlin},
title = {Chemoimmunotherapy With or Without Thoracic Radiotherapy for Elderly Patients in Advanced Non‐Small Cell Lung Cancer},
journal = {International Journal of Cancer},
year = {2026},
volume = {159},
number = {6},
pages = {1385--1390},
doi = {10.1002/ijc.70551}
}
EUVIMED